Dompé Looks Beyond In-Licensing
Mid-sized Italian drug firm Dompé has made its name as an astute local marketer. Yet the company is now talking up its in-house R&D programs, acknowledging that a pure in-licensing model may not work forever.
You may also be interested in...
Buying a foothold in Germany filled an important gap in Chiesi's European expansion strategy. But the privately owned Italian group may have to loosen up its dealmaking style to continue to clinch the deals it needs.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.